Biohaven licenses MoDE IgG degraders to Ono for Japan, South Korea, Taiwan and ASEAN for up to $100M

Biohaven has licensed its MoDE IgG degraders to Ono for Japan, South Korea, Taiwan and ASEAN, with up to $100M in near-term payments including an $80M upfront. BHV-1300 is in Phase 3 for Graves' disease.

Detected & updated continuously · Source: Nebula